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Abstract
In recent years, a small number of cells that have stem cell properties were identified in human gliomas called
brain tumor stem cells (BTSCs), which were thought to mainly contribute to the initiation and development of glio-
mas and could be identified by the surface marker CD133. However, recent studies indicated that the expression
of CD133 might be regulated by environmental conditions such as hypoxia and that there might be CD133−
BTSCs. Genetic mouse models demonstrated that some gliomas originated from transformed neural stem cells
(NSCs). Therefore, we investigated the expression of CD15, a surface marker for NSCs, in tumor spheres derived
from astrocytoma and ependymoma. CD15+ cells isolated from these tumor spheres had properties of BTSCs
including self-renewal, multidifferentiation, and the ability to recapitulate the phenocopy of primary tumors.
CD15 exhibited stable expression in long-term cultured tumor spheres, which sustained BTSCs properties, whereas
CD133 expression decreased significantly in late passages. Furthermore, CD15+CD133− cells isolated from early or
late passages of tumor spheres showed similar characteristics of BTSCs. Examination of glioma samples by immuno-
histochemistry showed that CD15 was expressed in a subset of human brain tumors. Therefore, CD15 can be used
as a marker of stem-like cells derived from brain tumors that might contain CD133− BTSCs.
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Introduction
The identification of brain tumor stem cells (BTSCs) marks a step to-
ward finding new and effective ways to treat malignant brain tumors,
one of the most lethal cancers afflicting both children and adults [1].
The concept of BTSCs has constructive significance for clinical practices
because it has been elucidated that BTSCs contribute to relapse and
chemoresistance or radioresistance of brain tumors [2–4]. To date, many
studies exploring the property of BTSCs built on the assumption that
BTSCs express a cell surface marker, CD133 [5,6].However, it has been
indicated that expression of CD133 could be regulated by environ-
mental conditions such as hypoxia [7], and contrary results have been
reported that there are CD133− BTSCs [8,9]. The existence of both
CD133-positive and -negative BTSCs implies that further characteriza-
tion of BTSCs is of tremendous interest. This also implies that one per-
sistent challenge is our inability to recognize BTSCs, and many issues
about the BTSCs are to be answered. For example, what is the signifi-
cance of CD133 expression in BTSCs? Are there other markers that
can specifically identify BTSCs? What is the relationship between
BTSCs and neural stem cells (NSCs)? Is glioma derived from ancestor
BTSCs or are BTSCs emerged after the forming of tumors?
The identification of NSCs provided new possible targets of tumori-
genic transformation of gliomas [10]. In fact, many evidences support
the idea that gliomas are derived from transformed NSCs [11]. Recent
studies using genetic mouse models suggested that at least a portion of
gliomas were originated from transformed NSCs, which have the char-
acteristics of reported BTSCs and are responsible for the formation of
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tumors [12,13]. In addition, many functional andmolecular similarities
have been elucidated between BTSCs and normal NSCs. Both BTSCs
and NSCs have immortal proliferative potential in the presence of epi-
dermal growth factor (EGF) and basic fibroblast growth factor (bFGF)
and can differentiate into neuronal and glia lineages when withdrawing
these growth factors and adding serum [6,14,15]. Both of them have an
environmental niche that is important for their maintenance of stem-
ness [16,17].Many signaling pathways critical for NSCs are also impor-
tant for BTSCs, but some of them were aberrantly regulated [4,18].
These facts imply that it would be necessary to study the relationship
between NSCs and BTSCs, and importantly, BTSCs might retain some
properties of NSCs.
NSCs in adult brains can be recognized by the surface marker
CD15 [19]. CD15 (leukocyte cluster of differentiation 15), which
is the trisaccharide 3-fucosyl-N -acetyllactosamine or FAL, also
known as stage-specific embryonic antigen 1 or leX antigen, is highly
expressed in many types of pluripotent stem cells [19]. Recent studies
suggested that, besides the traditionally recognized NSCs that reside
in the subventricular zone, CD133+/CD24− cells, but not CD24+
cells in the ependyma represent another population of NSCs [20].
Therefore, it is more likely that there are at least two types of NSCs
in normal brains identified by CD133 and CD15. However, to our
knowledge, although CD133 has been widely studied, the expression
of CD15 has not been fully explored in BTSCs. Previous studies fo-
cused on the expression of CD15 in gliomas got contradictory results
[21–24], and studies on BTSCs showed that glioma-derived neural
spheres expressed CD15 [15]. Given the similarity between NSCs
and BTSCs and recent disputes about CD133 as a BTSCs marker,
we performed this study to further explore the expression of CD15 in
BTSCs and to investigate if CD15 can be used to identify a group of
BTSCs different from CD133+ cells.
Materials and Methods
Glioma Samples
Seven glioma samples used for cell culture were provided by the
Department of Neurosurgery, Xijing Hospital, the Fourth Military
Medical University, including one grade 2 oligoastrocytoma, two ana-
plastic astrocytoma (World Health Organization [WHO] grade 3),
three glioblastoma (WHO grade 4), and one ependymoma (WHO
grade 2; Table 1). Additional 54 samples were used to investigate
CD15 expression in gliomas by Immunohistochemical analysis. Tumors
were histopathologically classified according to theWHO classification.
Informed consent was obtained from each patient, and experiments
were approved by the local ethics committee.
Culture of Primary Glioma Spheres
Samples were stored in Dulbecco’s modified Eagle’s medium
(DMEM)–F12 culture medium (Invitrogen, Carlsbad, CA) and pro-
cessed within 1 hour after resection. Tumor samples were washed by
DMEM-F12medium and incubated for 20minutes at 37°C in TrypLE
(Invitrogen). Then the tumor samples were dissociated to a single-cell
suspension using a fire-polished Pasteur pipette. The dissociated tumor
cells were centrifuged for 5 minutes at 800g and resuspended in either
serum-free medium (SFM) consisting of DMEM-F12 medium, EGF
(20 ng/ml; Invitrogen), bFGF (20 ng/ml; Invitrogen), and B27 (1:50;
Invitrogen) or serum-containing medium (SCM) consisting of DMEM-
F12 medium with 10% fetal bovine serum (Gibco BRL Life Technol-
ogies, Rockville, MD).
Limiting Dilution Assay and Primary Sphere Formation Assay
Limiting dilution assay was performed as described previously
[25]. Tumor spheres were washed and dissociated to a single-cell sus-
pension as described above. Then dissociated tumor cells were resus-
pended in DMEM-F12 medium to assess viable cell numbers by
Trypan Blue (Sigma, St Louis, MO) exclusion. Acutely dissociated
tumor cells were plated in 96-well microwell plates in 0.2 ml of
SFM. Final cell dilutions ranged from 200 cells per well to 1 cell per
well. Cultures were fed 0.025 ml of SFM every 2 days until day 14. The
percentage of wells not containing spheres for each cell plating density
were calculated and plotted against the number of cells per well. The
number of cells required to form one tumor sphere, which reflected the
proportion of tumor stem cells in the cell population, was then deter-
mined from the point at which the line crossed the 0.37 level. For pri-
mary sphere formation assays, this analysis was performed on the entire
acutely dissociated tumor cell population to quantify stem cell frequency
within the tumor.
Cell Proliferation Assays
Tumor spheres were dissociated and plated in 96-well microwell
plates in 0.2-ml volumes of SFM supplemented with growth factors
at a density of 2000 cells per well. Tumor spheres were collected from
six wells every 2 days after plating and dissociated to get single cells as
mentioned previously to assess the total number of cells.
Differentiation Assay of Tumor Spheres
Tumor spheres were plated onto glass coverslips coated with poly-
L-lysine (Sigma) in SCM in individual wells of a 24-well culture
plate. Cells were fed with SCM every 2 days, and coverslips were
processed at different days after plating.
Table 1. Summary of Patients Information.
Patients No. Sex Age (Years) Tumor Location Pathologic Subtype Tumor Sphere Formation
1 Female 32 Right lateral fissure Grade 3 astrocytoma 5 passages
2 Male 72 Right frontoparietal Grade 3 astrocytoma >20 passages
3 Male 44 Left parietal Grade 4/glioblastoma No
4 Female 8 Fourth ventricle Grade 2 ependymoma >10 passages*
5 Female 57 Right frontal Grade 4/glioblastoma >20 passages
6 Male 38 Right frontal Grade 2 oligoastrocytoma No
7 Female 31 Left parietal Grade 4/glioblastoma >10 passages
*Grew as adherent tumor spheres.
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Immunofluorescence
Immunofluorescence was performed on primary brain tumor stem–
like cells, serum-cultured cells, and glioma cell lines as described
previously [5]. Briefly, for immunostaining of undifferentiated tumor
spheres, cells were plated onto poly-L-lysine–coated glass coverslips in
SCM for 4 hours. Cells were then fixed with 4% paraformaldehyde and
incubated with the following antibodies: CD133/1 (1:50, mouse
monoclonal immunoglobulin G1 [IgG1]; Miltenyi Biotec, Bergisch
Gladbach, Germany), CD15 (1:150, MMA, mouse monoclonal; BD
Biosciences, San Jose, CA), Nestin (1:100, 10C2, mouse monoclonal;
Abcam, Cambridge, MA), β-III-tubulin (1:500, mouse monoclonal
IgG1; Abcam), NeuN (1:1000, mouse monoclonal IgG1; Chemicon,
Temecula, CA), glial fibrillary acidic protein (GFAP, 1:5000, rabbit
polyclonal; Abcam), Galc (1:200, rabbit polyclonal; Chemicon), and
Ki67 (1:100, rabbit monoclonal; Abcam). Appropriate secondary
antibodies (Texas Red goat antirabbit and Alexa 488 goat antimouse;
Molecular Probes, Invitrogen) were used. For immunostaining of dif-
ferentiated tumor cells, immunofluorescence was performed on differ-
entiated tumor spheres cultured in SCM. For immunostaining of
serum-cultured cells and glioma cell lines, serum-cultured cells and
U87, U251, and SHG44 glioma cells were plated onto glass coverslips
for 24 hours, and immunocytochemistry was performed as described
previously. Cells were additionally counterstained with Hoechst
33342 (Sigma) to permit counting of cell nuclei. Quantification of cells
stained with each antibody was averaged and estimated as a percentage
of total nuclei counted.
Isolation of CD15+ and CD15+CD133− Cells
CD15+ and CD15+CD133− cells were isolated by magnetic bead
sorting to investigate their capacity to form tumor spheres. Cultured
tumor spheres were dissociated to get single-cell suspensions as de-
scribed previously. Then, the dissociated cells were centrifuged at
800g for 5 minutes. Cells were incubated with anti-CD15 antibody
and biotin-conjugated secondary antibody. Then biotin-labeled cells
were rinsed and labeled by streptavidin-coupled Dynabeads (Dynal;
Invitrogen) for 30 minutes. Cells were rinsed with phosphate-buffered
saline during each step. Magnetic separation was carried out on the
Dynal magnet (Dynal; Invitrogen) to separate CD15+ and CD15− cells.
For CD15+CD133− cells, CD133− cells were negatively selected. Then
CD15+CD133− cells were isolated from theseCD133− cells as described
previously. After separation, tumor sphere formation and differentiation
assays were performed on CD15+, CD15−, and CD15+CD133− cells.
Chromosome Analysis
Cells were treated with 100 ml of Colcemid (10 g/ml; Invitrogen) for
2 hours. Then cells were resuspended in hypotonic solution (75 mM
KCl) for 30 minutes at 37°C, centrifuged, and fixed in methanol and
acetic acid. Metaphase spreads were prepared on slides, dried, and
Giemsa-stained after trypsin pretreatment.
Implantation into Nude Mice
Single cells dissociated from primary tumor spheres, isolated
CD15+, or CD15− cells were resuspended in 10 μl of phosphate-
buffered saline, in aliquots of 5000 or 10,000 cells. These aliquots were
injected stereotactically into the right striatum of 6- to 8-week-old nude
mice brains (n = 6 each; Center of Experimental Animals, Fourth Mil-
itary Medical University, Xian, China), after administration of general
anesthesia. The injection coordinates were 2 mm to the right of the
midline, 0.5 mm anterior to the coronal suture, and 3 mm deep.
The implanted mice were killed at 10 weeks after implantation by intra-
cardiac perfusion-fixation with 4% paraformaldehyde and examined for
tumors on the brain sections. All of the animals used were experimen-
ted in strict accordance with the animal experiments guidelines en-
forced at the Fourth Military Medical University.
Immunohistochemistry
For staining of human and mouse paraffin sections, tissue was
fixed overnight in 4% paraformaldehyde, transferred to 70% ethanol,
paraffin-embedded, and sectioned at a thickness of 1 μm. Sections
were mounted on microscope slides and then dried overnight at
60°C, dewaxed in xylene, and rehydrated with distilled water. Hema-
toxylin and eosin staining and immunohistochemical staining of the
following antibodies were performed on the sections: human-specific
Nestin (hNestin; 10C2, mouse monoclonal; Abcam), CD15, GFAP,
and β-III-tubulin. With the exception of sections stained for GFAP,
all sections were treated with heat-induced epitope retrieval technique
using a citrate buffer at pH 6.0. Then the sections were blocked for
endogenous peroxidase and biotin before the application of the primary
antibody. Incubation of primary antibodies was performed for 3 hours
at room temperature. The Elite Vector Stain ABC System (Vector Lab-
oratories, Burlingame, CA) was used as detection system and diamino-
benzidine was used as a chromogen. The counterstain of preference was
hematoxylin for nuclear detail.
Statistical Analysis
Statistical analyses were performed using Student’s 2-tailed t test. P <
.05 was considered statistically significant. Statistical analyses were done
using SPSS v.13.0.0 (SPSS, Inc, Chicago, IL).
Results
Formation of Tumor Spheres
SFM containing human recombinant EGF and bFGF were used
to favor the growth of glioma spheres. Glioma spheres from the seven
patients were presented as BTS1, BTS2, BTS3, BTS4, BTS5, BTS6,
and BTS7, and the cells cultured in SCM were marked correspond-
ingly as BT1, BT2, BT3, BT4, BT5, BT6, and BT7. Of the seven
brain tumor samples, numbers 1, 2, 4, 5, and 7 formed spheres within
1 month in SFM (Table 1). BTS1 sustained five passages and ceased
growth. BTS2, BTS4, BTS5, and BTS7 have been cultured more than
10 passages (BTS2 and BTS5 for more than 20 passages) and were
sustained now. However, tumor cells from samples 3 and 6 did not
form tumor spheres within 1 month. Of the formed tumor spheres,
BTS1, BTS2, BTS5, and BTS7 grew as floating spheres, whereas
BTS4 grew as adherent tumor spheres (Figure 1A ), consistent with
previous report that some tumor spheres grew as adherent spheres
[8]. The morphologies of the seven SCM cultured cells were also dif-
ferent from each other (Figure 1A). When SCM-cultured tumor cells of
late passages (passage 10) were transformed to SFM, no tumor spheres
were investigated within 1 month.
Primary sphere formation assay showed that the stem cell frequen-
cies in the investigated samples (samples 1, 2, 4, 5, and 7) were be-
tween 3.7% and 20.1% (12.48% ± 6.53%). Tumor spheres cultured
in SFM grew at a relatively slow rate at the first two passages, whereas
they got a constant and greater growth rate after two passages
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(Figure 1B ). Most SCM-cultured tumor cells showed a highly het-
erogeneous morphology and proliferated at constant rates. BT2
showed initial growth followed by a plateau phase, and then some
cells got a much greater growth rate and proliferated dominantly at
later passages (Figure 1C ). For ependymoma-derived tumor spheres
that showed adherent growth pattern, BTS4 exhibited constant and a
relatively slow growth rate (Figure 1, D and E ).
Primary Tumor Spheres Cultured in SFM Showed
BTSCs Properties
Besides BTS1, tumor spheres (BTS2, BTS4, BTS5, and BTS7)
cultured in SFM could be serially passaged more than 10 times (Ta-
ble 1), indicating that these stem-like cells have the potential of self-
renewal, one critical feature of BTSCs. Immunofluorescence staining
showed that both astrocytoma- and ependymoma-derived spheres
Figure 1. Morphologies and proliferation kinetics of SFM- and SCM-cultured cells. (A) Morphologies of SFM-cultured stem-like tumor
spheres (BTS2 and BTS4) and serum-cultured cells (BT2 and BT4) from different passages (p2 indicates passage 2; p10, passage 10). Tumor
spheres BTS2 cultured in SFM showed constant morphology, whereas SCM-cultured cells changed apparently after long-term culturing.
BTS2 got constant growth rate after first two passages (B). BT2 got extraordinary proliferation potential after a plateau at about passage 2 (C).
BTS4 (D) and BT4 (E) showed slow and constant growth rate. Data represent mean values ± SD of three independent experiments.
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expressed stem cell markers CD133, Nestin, CD15 (Figure 2, A–F ),
and proliferative marker Ki67 (Figure 2, G and H ). One property of
BTSCs was their potential to differentiate in serum medium without
growth factors. Therefore, differentiation potential was examined in
all cultured tumor spheres. Tumor spheres of BTS1, BTS2, BTS4,
BTS5, and BTS7 were plated onto poly-L-lysine–coated coverslips
and cultured in SCM. After culturing in this differentiation medium,
all tumor spheres adhered and cells migrated from the spheres
(Figure 3A). Immunofluorescence staining showed that neuronal
and glial lineage markers NeuN, β-III-tubulin, GFAP, and Galc were
expressed in the differentiated cells. However, a considerable portion
of differentiated cells expressed both neuronal and glial markers, im-
plying the aberrant differentiation of tumor stem–like cells (Figure 3B ).
CD15+ Cells Isolated from Tumor Spheres Showed Potential
of BTSCs
It has been suggested that CD15 was a marker of NSCs. We detected
the expression of CD15 in early passages (passage 2) of SFM-cultured
tumor spheres. As a result, CD15 was detected in all the tumor spheres
derived from the five samples that formed stem cell–like spheres (Fig-
ure 2, C and F ), including BTS1 that sustained only five passages. In-
terestingly, although it was elucidated that CD15 was not expressed in
normal ependyma cells [19], CD15 was detected in ependymoma-
derived tumor spheres (Figure 2F ). Immunostaining for proliferative
marker Ki67 showed that some CD15+ cells were positive for Ki67
(Figure 2, G and H ), indicating that brain tumor stem–like cells
showed increased proliferative capacity [6].
Then we assessed if CD15 can identify stem cells in these tumor
spheres. CD15-positive cells were isolated by magnetic bead sorting
from BTS1, BTS2, BTS4, BTS5, and BTS7. Both CD15-positive
and CD15-negative cells were cultured in SFM to investigate their
potential to form stem-like spheres. CD15+ cells formed tumor
spheres within 1 week, whereas few CD15-negative cells formed tu-
mor spheres within 2 weeks (Figure 3, C and D). The percentage of
formed tumor spheres in CD15-positive and CD15-negative cells
were 41.6% ± 3.2% and 1.1% ± 0.4%, respectively (P < .001). Tu-
mor spheres formed by CD15+ cells (CD15-TS) could be dissociated
and form secondary tumor spheres, similar to their parental spheres.
Besides CD15-TS from BTS1 that sustained three to four passages,
CD15-TS from BTS2, BTS4, BTS5, and BTS7 were serially pas-
saged more than five times, indicating their self-renewal capacity.
When CD15-TS were induced to differentiation, both neuronal and
glial cell markers β-III-tubulin, NeuN, GFAP, and Galc were expressed
(Figure 3, E–H ). Like their parental tumor spheres, CD15-TS showed
aberrant differentiation with many cells that expressed both neuronal
and glial cell markers (Figure 3, I and J ). Quantification of differen-
tiated cells showed that percentages of GFAP, β-III-tubulin, Galc-
positive, and GFAP, β-III-tubulin double-positive cells in differentiated
cells from CD15-TS were similar to those of their parental tumor
spheres (Figure 3B ).
CD15+ Cells Displayed Tumor-Specific Properties
In addition to forming stem-like neural spheres in SFM, BTSCs
were expected to bear some tumor-specific features, such as unbalanced
karyotypes. We conducted chromosome analysis on SFM- and SCM-
cultured cells to demonstrate that cells in tumor spheres and CD15+
cells were indeed transformed and are not normal NSCs. For each
Figure 2. Expression of stem cell markers and proliferate marker Ki67 in stem-like tumor spheres. (A–F) Tumor spheres BTS2 and BTS4
were shown as representative to be labeled with antibodies to CD133, Nestin, and CD15 (green). Nuclei were counterstained with
Hoechst 33342. The merged images were also shown. Some CD15+ cells were Ki67-positive investigated in both tumor spheres (G)
and dissociated single cells (H).
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SFM-cultured cell line (BTS2, BTS4, BTS5, and BTS7), identical ab-
normal numerical chromosomal aberrations were present in tumor
sphere or CD15+ cells of both early and late passages (passages 2 and
10). As a representative, identical numerical chromosomal aberrations
47 XY, −10, +7, +21, were detected in BTS2 cells and CD15+ BTS2
cells of early and late passages (Figure 4A). However, for SCM-cultured
tumor cells, more complicated numerical chromosomal aberrations
were present in late passages (data not shown). These results suggested
that stem-like cells cultured in SFM retained their property with little
changes, whereas tumor cells cultured in SCM showed chromosome
instability at late passages [15].
CD15+ Cells Showed Tumorigenesis In Vivo
CD15+ cells were isolated from expanded BTS2, BTS4, and
BTS5. Then CD15+ and CD15− cells, SCM-cultured cells BT2,
BT4, and BT5 were injected into nude mice brains, in aliquots of
5000 or 10,000 cells to investigate their potential to form tumors
in vivo. The mice were killed at 10 weeks after transplantation for
examination of tumors. All of the nude mice that received CD15+
cells developed tumors (Figure 4B ), whereas none of the mice injected
with SCM-cultured cells or CD15− cells formed tumors. Anti–human
Nestin-10C2 antibody (hNestin; Abcam), which does not react with
mouse antigens, was used to specifically recognize human-derived cells
expressing Nestin. Brains of normal nude mice were used as negative
controls. hNestin was not detected in normal nude mice brain, indicat-
ing that Nestin-positive cells detected in xenografts would be derived
from human tumor cells. hNestin-positive cells in the xenograft tu-
mors demonstrated extensive infiltration into the surrounding cerebral
cortex, a pathologic feature of human gliomas (Figure 4C ). Furthermore,
hNestin-positive cells showed a tendency for migrating along white
matter tracts such as the corpus callosum (Figure 4D), as is characteris-
tically seen with glioma cells in the brains of patients. Immunohistologic
Figure 3. Differentiation of tumor spheres (BTS2 was shown as representative) in SCM. (A) Cells in tumor spheres cultured in SCMmigrated
from the spheres and differentiated into glial and neuronal lineages. (B) Differentiated cells positive for each antigen and double-positive for
glial and neuronal antigen were counted (p2 indicates BTS2 at passage 2; p2CD15+, CD15-TS from passage 2; p2CD15+CD133−, tumor
spheres formed by CD15+CD133− cells of passage 2; p10CD15+, CD15-TS from passage 10. Columns represent mean values ± SD of
three independent experiments). CD15+ cells formed tumor spheres in SFM (C), whereas CD15− cells did not (D). (E–H) Differentiated cells
from the tumor spheres showed expression of neuronal marker β-III-tubulin and NeuN, astrocyte marker GFAP, and oligodendrocyte marker
Galc. (I and J) Some differentiated cells expressed both neuronal and glial markers. β tub indicates β-III-tubulin.
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staining showed that CD15 was expressed in both primary tumor sam-
ples and tumor xenografts (Figure 4, E and I ). Examination of Nestin,
GFAP, and β-III-tubulin expression showed that primary and xenografts
tumors had similar immunohistologic characteristics (Figure 4, E–L).
These data demonstrate that CD15+ cells have the potential to form
tumors in vivo, a critical property of BTSCs.
CD15 Expression Was Decreased in Differentiated
Tumor Spheres
To further confirm if CD15 was predominantly expressed in stem-
like tumor cells, we examined CD15 expression in differentiated cells
and serum-cultured cells (Figure 5, A–D). Decrease of CD15 expres-
sion was detected in all SFM-cultured cell lines after they were trans-
formed to SCM. After 4 days of differentiation, CD15 was significantly
decreased in the tumor spheres and was not expressed in the migrated
cells (Figure 5A). After 14 days of differentiation, CD15was almost not
detected. These results meant that CD15 expression declined with the
differentiation of BTSCs and was little or not expressed in more mature
cells (Figure 5E ).
Primary tumor cells were also cultured in SCM. Although inves-
tigated in dissociated single cells from primary tumors (Figure 5B ),
CD15was not detected in serum-cultured cells (BT1-BT7; Figure 5C ).
We also tested if standard glioma cell lines cultured in serum medium
contain CD15+ cells. We performed immunostaining in U87, U251,
and SHG44 cell lines, but CD15 was not detected in these cell lines
(Figure 5D). These results indicated that CD15 was not expressed in
cells cultured in serum medium, in which stem-like cells were differ-
entiated. These results also implied that serum-cultured cells and
standard glioma cell lines shared many important properties different
from SFM-cultured stem-like cells and primary tumors [15].
CD15 Identified BTSCs in Tumor Spheres of Late Passages
Because long-term culture might influence the expression of
CD133, we also examined the expression of CD133 and CD15 in
late passages of tumor spheres. In late passages (passage 10), the per-
centage of CD133+ cells were decreased significantly, whereas de-
creased percentage of CD15+ cells were hardly appreciable (Figure 5,
F and G ). Limiting dilution assay showed that stem-like cell frequen-
cies in early and late tumor spheres were similar (Figure 5H ). In addi-
tion, differentiation assay showed that CD15-TS from early and late
passages had similar potential to differentiate into neuronal and glial
lineages (Figure 3B). Together with the result that karyotype of BTSCs
was stable in late passages, these facts suggested that SFM-cultured cells
maintained their stem cell properties even in late passages and that de-
creased percentage of CD133+ cells in late passages might be, at least
partly, due to the environmental factors as have been elucidated but not
necessarily decreased stem cell potentials. Therefore, stable expression
of CD15 made it more suitable to identify BTSCs from tumor spheres,
especially of late passages.
CD15+ Cells Might Contain BTSCs That Are
CD133 Negative
To further investigate if CD15+ cells represent one type of BTSCs
different from CD133+ cells, we isolated CD15+CD133− cells and
Figure 4. CD15+ cells showed aberrant karyotypes and tumorigenesis in vivo (data from BTS2 was shown as representative). (A) Chro-
mosome analysis demonstrated that CD15+ cells from BTS2 showed numerical chromosomal aberrations 47 XY, −10, +7, +21. He-
matoxylin and eosin (B) and anti-hNestin staining (C, D) of intracranial xenograft formed by CD15+ cells transplanted into nude mice
brains. Anti-hNestin staining showed that hNestin+ cells infiltrated into surrounding brain tissues (C) and migrated along the corpus
callosum (D, a higher magnification of the box in C). (E–L) Immunohistologic staining for Nestin (E, I), CD15 (F, J), GFAP (G, K), and
β-III-tubulin (βtub; H, L) showed that primary (E–H) and xenografts (I–L) tumors had similar immunohistologic characteristics.
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tested if they have stem cell activities. CD15+CD133− cells could be
isolated from all SFM-cultured tumor spheres of both early (passage 2)
and late passages (passage 10, except BTS1). Tumor sphere forma-
tion assay and differentiation assay showed that CD15+CD133− cells
could also form tumor spheres in SFM, and cells in these tumor
spheres differentiated into glial and neuronal lineages in SCM (Fig-
ure 5, I–K ; Figure 3B ). Then CD15+ cells isolated from tumor
spheres formed by CD15+CD133− cells of late passages were injected
into nude mice brains. Xenografts similar to those formed by early
CD15+ cells were investigated. Therefore, CD15 might identify
BTSCs that contain CD133− cells from both early and late passages
of tumor spheres.
CD15 Was Expressed in a Subset of Human Brain Tumors
To determine whether CD15 is expressed in human brain tumors, we
performed immunohistochemical analysis on 54 archival brain tumor
samples, including 20 grade 4 glioblastomas, 11 grade 3 astrocytomas,
17 grade 2 astrocytomas, and 4 ependymomas. Immunoreactivity for
CD15 in granulocytes was detected in all cases, serving as an internal
positive control (Figure 6A ). Primary antibody omission was used as
negative control. CD15 was investigated in a portion of all types of
astrocytomas and ependymomas (Figure 6, B–F ). This means a subset
of brain tumors contained CD15+ stem- or progenitor-like cells, which
might have originated from transformed neural stem or progenitor cells
and responsible for the development of tumors.
Discussion
In recent years, the concept of cancer stem cells (CSCs) gives us new
insights about the tumor biology. The CSC hypothesis claimed that
tumors were driven by a rear population of cells, CSCs, which have
the potential of self-renewal, multidifferentiation, and the ability to
recapitulate the phenotype of origin tumors. Although there are con-
troversies [26], the research about CSCs progressed rapidly in recent
years and gave researchers new direction to find more effective ther-
apies. For brain tumor, the identification of BTSCs leads to promis-
ing progress in treating gliomas [4,6,27]. However, some critical
problems are needed to be solved to get substantial understanding
of BTSCs. First, the identity of BTSCs is not clear. Present isolation
methods, including isolation based on surface marker CD133 or side
population, have led to disputed results of identifying BTSCs
Figure 5. CD15 expression and stem cell properties in differentiated and late-passage tumor spheres. (A) Expression of CD15 decreased
significantly after differentiation. (B) CD15-positive cells were detected in the primary dissociated cells. Arrows in panels A and B indi-
cate CD15+ cells, arrowhead in panel B indicates CD15− cells migrated from the tumor spheres. (C and D) CD15 was not detected in
serum-cultured cells or standard glioma cell lines. (E) Stem cell markers CD15, CD133, and Nestin were downregulated in differentiated
tumor spheres. (F and G) Percentage of CD133-positive cells was decreased at late passages, whereas decrease of CD15 expression
was not appreciable. (H) Limiting dilution assay showed that BTS2 cells had similar potential in forming tumor spheres at early and late
passages. (I–K) CD15+CD133− cells formed tumor spheres in SFM expressing Nestin (I), which differentiated to glial and neuronal
lineages in SCM (J, K). Nestin expression was decreased in differentiated cells (J). Data from tumor sample 2 (BTS2 or BT2) were shown
as representative in panels A–C, E, H, and I–K. p2 indicates passage 2; p10, passage 10. Columns represent mean values ± SD of three
independent experiments. (E) *P < .05 versus undifferentiated. (F) *P < .05 versus p2.
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[8,28,29]. Second, the origin of BTSCs and its relationship with
NSCs are not clear [30]. These problems mean that we only have
little knowledge about BTSCs, and further studies are needed to ex-
plore the characteristics of BTSCs.
Previous studies showed that single cells from primary gliomas
formed tumor spheres in SFM containing EGF and bFGF. This
method has been used for many years to study NSCs. Only stem
or progenitor cells survive in this medium, whereas differentiated ma-
ture cells die, and progenitor cells can only sustain limited passages.
In recent years, this medium has been used to enrich stem cells from
human brain tumors [6,15]. In our study, tumor cells cultured in
SFM showed a relatively slow growth rate within the first two pas-
sages and got greater and achieved a constant growth rate after two
passages, possibly reflecting the select process of this SFM culture
system for stem-like cells. In the early passages, differentiated, more
mature progenitor and other cells gradually disappeared, and the
BTSCs pool survived and proliferated. During late passages, most
cells in tumor spheres were stem or progenitor cells and, therefore,
showed constant growth rate. As a result, we got brain tumor spheres
containing BTSCs from both glioma and ependymoma cultured in
SFM. In our results, 5 (71.43%) in 7 samples formed tumor spheres
within 1 month and 4 sustained more than 10 passages.
Recent studies showed that not all CD133-positive cells were
BTSCs, and there were CD133-negative BTSCs [8,9,28]. For exam-
ple, A2B5+ CD133− brain tumor–initiating cells were identified re-
cently [31]. In addition, the significance of CD133 expression in
BTSCs was not clear [32]. It has long been hypothesized that brain
tumors might have originated from NSCs [11]. Exploration of the
mechanisms of glioma tumorigenesis using genetic mouse models
implied that at least a part of the gliomas might have originated from
transformed NSCs [12,13]. Therefore, we examined the expression
of CD15, a marker of NSCs, in tumor spheres to assess if CD15 can
be used to enrich BTSCs.
CD15 is expressed in many pluripotent stem cells, including plu-
ripotent embryonic stem cells, in germinal zones of the developing
CNS, on some astrocytes in the adult CNS, and within adult neu-
rogenic zones. CD15 has been identified as one specific marker for
NSCs [19] and, recently, as a marker for tumor-propagating cells in
medulloblastoma [33]. Our results demonstrated that CD15 was ex-
pressed in both glioma- and ependymoma-derived tumor spheres and
that its expression decreased dramatically in differentiated tumor
spheres. In addition, CD15 was not expressed in SCM-cultured cells
and standard glioma cell lines, which have been suggested not con-
taining stem cells. In fact, serum-cultured cell lines were quite differ-
ent from stem-like cells in many facets. For example, SFM-cultured
stem-like cells, but not serum-cultured primary cells or standard gli-
oma cells lines (U251, U87 cells, etc.), phenocopied the critically im-
portant histopathologic features of the original human gliomas [15].
Another difference between SFM- and SCM-cultured cells was their
stability of critical features. We analyzed the chromosomes of differ-
ent passages of both SFM- and SCM-cultured cells and found that
SFM-cultured tumor spheres largely maintained their initial geno-
types, whereas, in contrast, SCM-cultured cells showed quite com-
plex changes of genotypes. Together, these results indicated that
CD15 was expressed mainly in stem-like brain tumor cells.
CD15 has been described as an NSC marker that did not contain
the ependyma cells [19]. Recent studies elucidated that other types of
CD133-positive NSCs residing in the ependyma were different from
CD15+ NSCs because CD15 was not expressed in ependyma cells
[20,34]. These facts complicated the issue of origin of BTSCs and
indicated that BTSCs may also contain different types of “stem cells,”
which probably originated from different types of NSCs or progeni-
tors. It was not clear which type of NSCs, CD15+ NSCs or CD133+
NSCs, was more early, or if they represented different lineages of
NSCs. Although we did not directly elucidate the existence of
CD15+CD133+ cells, the percentage of CD15+ cells and CD133+
cells in early passages (e.g., 76.5% ± 0.5% and 53.3% ± 4.1%, re-
spectively, for BTS2; Figure 5E ) in tumor spheres indicated that
there were CD15+CD133+ BTSCs. This is different from the situa-
tions in normal nervous systems, where CD15 and CD133 were ex-
pressed by different cells. Whatever the origin of BTSCs and the
relationship between CD15+ and CD133+ NSCs, both expressions
of CD15 and CD133 in BTSCs implied that the identified stem-
like cells from brain tumors did have the property of stem cells
Figure 6. Expression of CD15 in human brain tumors. (A) CD15 was detected in granulocytes, serving as an internal positive control. (B–E)
CD15 was investigated in glioblastoma (B), grade 3 astrocytoma (C), grade 2 astrocytoma (D), and ependymoma (E). (F) Summary of CD15
detection in brain tumors.
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but were aberrantly transformed. In addition, the expression of
CD15 in ependymoma-derived tumor spheres also implied the aber-
rant phenotype of these stem-like tumor cells.
Consistent with other reports [12,35], we investigated down-
regulation of CD133 in late passages of stem-like cells. In addition,
CD133 might fail to accurately identify stem-like cells in late pas-
sages, whereas CD15 retained its property even at late passages. Re-
cent studies discovering some mechanisms that regulate expression of
CD133 in brain tumor cells indicated that expression of CD133
could be regulated by environmental conditions such as hypoxia
and mitochondrial dysfunction [7]. The mechanisms of regulation
of CD133 expression in brain tumors need to be further examined
to elucidate their roles in stem-like cells.
The expression of CD15 in BTS1, which sustained only five pas-
sages, indicated that CD15 was also expressed in some progenitor
cells. However, the existence of CD15+CD133− BTSCs demonstrated
that CD15might be onemarker for BTSCs, which containedCD133−
cells. Our results and other reports indicated that CD133 was not ex-
pressed in all brain tumors (data not shown) [36,37]. Therefore, CD15
would be used as onemarker to identify BTSCs from brain tumors that
do not express CD133. The expression of the NSC marker CD15 in
brain tumor stem–like cells implied some intrinsic relationships be-
tween NSCs and BTSCs. The expression of the NSCs marker
CD15 indicated that BTSCs might retain more characteristics of
NSCs besides self-renewal and multidifferentiation.
These results raised other questions about NSCs and BTSCs such
as the following: What is the relationship between CD15+ and
CD133+ NSCs and BTSCs? How have CD15 and CD133 appeared
during the formation of gliomas? Answers to these questions would
lend credence to the identity of BTSCs and provide novel strategies
to target these aberrantly transformed stem-like cells.
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